What's Happening?
Arima Genomics, Inc., a cancer diagnostics company, has announced results from a study conducted with Duke University, published in Blood Advances, demonstrating that its Hi-C technology can identify clinically important structural rearrangements in diffuse
large B-cell lymphoma (DLBCL) that are missed or not evaluated by routine fluorescence in situ hybridization (FISH). The study evaluated Arima's proprietary Hi-C sequencing approach, which is used in its Aventa Lymphoma clinical test. Researchers analyzed archival FFPE specimens from 159 DLBCL patients who had previously undergone FISH testing for MYC, BCL2, and BCL6 rearrangements. Arima Hi-C detected 96% of adjudicated MYC, BCL2, and BCL6 rearrangements, compared to 76% by FISH. Notably, Arima Hi-C identified 25 rearrangements that FISH missed and also found 45 additional clinically relevant rearrangements or fusions in 42 patients, involving genes like CCND1, CCND3, IRF4, PD-L1, ALK, MALT1, and ATM.
Why It's Important?
This study highlights a significant advancement in cancer diagnostics, particularly for lymphoma. The ability of Arima Hi-C technology to detect a broader range of clinically important rearrangements, including those missed by conventional FISH testing, can lead to more accurate diagnoses, better classification of lymphoma types, and more effective treatment planning. For instance, concurrent MYC and BCL2 rearrangements define a distinct high-grade B-cell lymphoma entity, impacting risk assessment and treatment. The additional findings, such as those involving CCND1, IRF4, ALK, and MALT1, provide crucial diagnostic context and can influence treatment decisions, including eligibility for clinical trials (e.g., with PD-L1 rearrangements). This improved genomic profiling can directly impact patient outcomes by guiding oncologists toward more personalized and targeted therapies, especially in complex cases where existing findings are insufficient for a definitive diagnosis.
What's Next?
Arima Genomics plans to continue developing its analysis methods to reveal other genomic variants, such as copy number variants and small variants, in future products, aiming for truly comprehensive genomic profiling of tumors. The Aventa Lymphoma test, leveraging Hi-C sequencing technology, is designed to identify clinically relevant rearrangements without requiring predefined breakpoint locations or fusion partners, offering a broader structural view. The company's CLIA-certified laboratory in Orlando, Florida, will continue to offer testing for solid tumors and lymphoma. The findings suggest a shift towards more advanced genomic sequencing technologies in clinical practice, potentially leading to a re-evaluation of standard diagnostic protocols for lymphomas and other cancers.
Beyond the Headlines
The transition from targeted genetic testing methods like FISH to broader, more comprehensive genomic profiling technologies like Hi-C represents a paradigm shift in precision medicine. This development underscores the increasing role of advanced bioinformatics and molecular biology in clinical diagnostics. The ethical implications include ensuring equitable access to these sophisticated tests and managing the vast amount of genomic data generated. Legally, the integration of such detailed genomic information into patient care will require robust frameworks for data privacy and informed consent. Culturally, it signifies a move towards a more individualized approach to healthcare, where treatment decisions are increasingly tailored to the unique genetic makeup of a patient's tumor, potentially transforming the landscape of cancer care.
